Keywords
Thrombolytic therapy
Urokinase
Teneplase
Submitted : 2024-04-09
Accepted : 2024-04-24
Published : 2024-05-09
Abstract
Acute myocardial infarction has become a serious disease that affects the quality of contemporary human survival, and improved efficacy and risk avoidance can be achieved through the upgrading of thrombolytic drugs and precise intervention. This article takes the development of three generations of thrombolytic drugs as the main line, and combs through the development of thrombolytic drugs from the era of urokinase and streptokinase to Alteplase and single-chain urokinase-type fibrinogen activator and their respective advantages and disadvantages. The advantages of three generations of tissue-type fibrinogen kinase derivatives, Reteplase, and tenecteplase, are compared and described in this article.
References
Ma C, Deng M, 2021, Progress of Intravenous Thrombolysis for Acute Myocardial Infarction with Urokinase Proteins. Zhejiang Journal of Integrative Medicine, 31(3): 292–294.
Yi J, Zheng X, 2020, Progress of Antiplatelet Therapy in Thrombolyzed Patients with Acute ST-Segment Elevation Myocardial Infarction. Journal of Clinical Cardiovascular Disease, 36(6): 502–505.
Lin R, Qiu L, Wu B, 2020, Commonly Used Thrombolytic Drugs for ST-Segment Elevation Myocardial Infarction and Its Progress. Chinese Journal of Frontiers of Medicine (Electronic Edition), 12(6): 16–21.
Shen Z, 2020, The Status of Thrombolytic Technology in the Treatment of ST-Segment Elevation Myocardial Infarction. Concord Medical Journal, 11(2): 127–129.
Hu W, Gao W, Yao Y, et al., 2022, High-Risk Factors for the Occurrence of Symptom Fluctuation After Thrombolytic Therapy in Elderly Patients with Acute Cerebral Infarction in an Emergency Setting. Chinese Journal of Gerontology, 42(20): 4937–4939.
Lu Z, Zhang F, 2022, Observation on the Efficacy and Safety of Atorvastatin Applied Before and After Intravenous Thrombolysis in Patients with Acute Cerebral Infarction. Guizhou Medicine, 46(9): 1434–1435.
Mu F, Song W, 2022, Effect of Timing of Recombinant Tissue-Type Plasminogen Activator (rt-PA) Intravenous Thrombolysis on the Efficacy and Prognosis of Patients with Acute Cerebral Infarction. Thrombosis and Hemostasis, 28(3): 546–548 + 552.
Yang L, Zhang Y, Ge W, et al., 2022, Comparison of the Safety of Intravenous Thrombolysis with rt-PA and Urokinase in the Treatment of Acute Cerebral Infarction and Its Effect on Thromboelastography. Journal of Stroke and Neurologic Diseases, 39(1): 43–45.
Cai Y, 2020, Observation on the Efficacy of Drug Combined with Thrombolysis in the Treatment of Acute ST-Segment Elevation Myocardial Infarction. Heilongjiang Medicine, 33(4): 818–820.
Wang W, Xu J, Zhang H, et al., 2022, Analysis of Factors Affecting Early Neurological Deterioration After Intravenous Thrombolysis in Elderly Patients with Acute Cerebral Infarction. Thrombosis and Hemostasis, 28(3): 364–366.